SBIR-STTR Award

Development of Alkontrol Herbal for Treating Alcohol Abuse
Award last edited on: 3/27/2019

Sponsored Program
STTR
Awarding Agency
NIH : NIAAA
Total Award Amount
$1,154,747
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Haixia Li

Company Information

Natural Pharmacia International Inc (AKA: NPI)

121 Middlesex Turnpike Unit 5
Burlington, MA 01803
   (781) 272-6888
   tlee@natural-pharma.com
   www.natural-pharma.com

Research Institution

McLean Hospital

Phase I

Contract Number: 1R42AA022577-01A1
Start Date: 9/20/2016    Completed: 8/31/2017
Phase I year
2016
Phase I Amount
$154,747
This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International, Inc. (NPI) and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism. Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders, including fetal alcohol syndrome, fatal motor crashes, accidents and homicides. On college campuses alone, alcohol use results annually in almost 2,000 deaths, 100,000 sexual assaults, 600,000 injuries, and 700,000 assaults. For most, problematic drinking and its associated morbidity will not be brought to the attention of Primary Care Professionals and so many go without treatment. This is precisely where an OTC herbal product could have the greatest impact. An extract of kudzu (Pueraria lobata) has been patented by McLean Hospital and licensed it to NPI under the name Alkontrol-herbal. Over the past 13 years, our team has extensively studied this kudzu extract and demonstrated its safety and efficacy in healthy control subjects as well as in heavy binge drinkers. The reason for pursuing the STTR mechanism is two-fold: 1) while NPI has been able to produce enough product for our modest clinical studies, they are not in a position to ramp up full production in order to support larger scale clinical trials; and 2) we have conducted and published 6 studies in human subjects, but we have yet to conduct a study in heavy drinkers who are alcohol-dependent and are treatment-seeking. Thus, there is a significant need for this clinical trial to demonstrate efficacy in this important population. The reason for the Fast Track approach is that we have already developed product, licensed it to NPI, and have the backbone of a commercialization plan, but need fiscal support to develop the processes needed to increase production of enough standardized product to support not only the clinical trial, but to be able to meet the needs once the commercialization plan is implemented. Thus Phase I will be focused on providing NPI with the infrastructure to scale up production of standardized, high quality Alkontrol- herbal while the clinical trial will be the major milestone of Phase II. Collectively, successful completion of thes two phases will pave the way for the commercialization of Alkontrol-herbal. Key milestones for Phase I include: procure and authenticate Pueraria lobata from our source in China, perform GMP extraction and precipitation, develop independent QC analytical protocols, optimize ratio of isoflavones, and finalize submission of an IND for FDA-approved labeling and IRB applications. Phase II milestones include: scale up production of Alkontrol- herbal, isolate puerarin for standardization, develop a urinary biomarker for medication adherence and conduct proof-of-concept clinical trial in treatment-seeking alcohol-dependent individuals.

Public Health Relevance Statement:


Public Health Relevance:
The proposed STTR project represents a collaboration between the small business Natural Pharmacia International, Inc. and McLean Hospital to ramp up production of Alkontrol-herbal and conduct a clinical trial in treatment-seeking alcohol dependent, heavy-drinking individuals.

Project Terms:
Accidents; Accounting; Acute; Adverse effects; Alcohol abuse; alcohol abuse therapy; Alcohol consumption; Alcohol dependence; alcohol use disorder; Alcoholic beverage heavy drinker; Alcoholism; Alcohols; analytical method; assault; Attention; Award; Back; binge drinker; binge drinking; Biological Assay; Biological Availability; Biological Markers; Botanicals; Businesses; Cessation of life; China; Clinical Research; Clinical Trials; Collaborations; college; commercialization; daidzin; Development; Dose; drinking; Drug Kinetics; FDA approved; Fetal Alcohol Syndrome; Heavy Drinking; High Pressure Liquid Chromatography; Homicide; Hospitals; human subject; Human Volunteers; Individual; Injury; Institutional Review Boards; International; Isoflavones; Kudzu; Label; Laboratories; Laboratory Study; Legal patent; Licensing; Marketing; Measures; medical schools; medication compliance; meetings; Methods; Modeling; Monitor; Morbidity - disease rate; Motor; Names; National Institute on Alcohol Abuse and Alcoholism; Outpatients; Pattern; Performance; Persons; Pharmaceutical Preparations; Phase; Plants; Plasma; Population; Positioning Attribute; Precipitation; Preparation; Primary Health Care; Procedures; Process; product development; Production; Property; Protocols documentation; Public Health; public health relevance; Publishing; Pueraria lobata; puerarin; Quality Control; Ramp; Reporting; Research Infrastructure; Safety; scale up; sexual assault; Sleep Wake Cycle; Small Business Technology Transfer Research; Source; Standardization; Testing; Time; treatment duration; urinary; Vertebral column; Work

Phase II

Contract Number: 4R42AA022577-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2017
(last award dollars: 2018)
Phase II Amount
$1,000,000

This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International, Inc. (NPI) and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism. Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders, including fetal alcohol syndrome, fatal motor crashes, accidents and homicides. On college campuses alone, alcohol use results annually in almost 2,000 deaths, 100,000 sexual assaults, 600,000 injuries, and 700,000 assaults. For most, problematic drinking and its associated morbidity will not be brought to the attention of Primary Care Professionals and so many go without treatment. This is precisely where an OTC herbal product could have the greatest impact. An extract of kudzu (Pueraria lobata) has been patented by McLean Hospital and licensed it to NPI under the name Alkontrol-herbal. Over the past 13 years, our team has extensively studied this kudzu extract and demonstrated its safety and efficacy in healthy control subjects as well as in heavy binge drinkers. The reason for pursuing the STTR mechanism is two-fold: 1) while NPI has been able to produce enough product for our modest clinical studies, they are not in a position to ramp up full production in order to support larger scale clinical trials; and 2) we have conducted and published 6 studies in human subjects, but we have yet to conduct a study in heavy drinkers who are alcohol-dependent and are treatment-seeking. Thus, there is a significant need for this clinical trial to demonstrate efficacy in this important population. The reason for the Fast Track approach is that we have already developed product, licensed it to NPI, and have the backbone of a commercialization plan, but need fiscal support to develop the processes needed to increase production of enough standardized product to support not only the clinical trial, but to be able to meet the needs once the commercialization plan is implemented. Thus Phase I will be focused on providing NPI with the infrastructure to scale up production of standardized, high quality Alkontrolherbal while the clinical trial will be the major milestone of Phase II. Collectively, successful completion of these two phases will pave the way for the commercialization of Alkontrol-herbal. Key milestones for Phase I include: procure and authenticate Pueraria lobata from our source in China, perform GMP extraction and precipitation, develop independent QC analytical protocols, optimize ratio of isoflavones, and finalize submission of an IND for FDA-approved labeling and IRB applications. Phase II milestones include: scale up production of Alkontrolherbal, isolate puerarin for standardization, develop a urinary biomarker for medication adherence and conduct proof-of-concept clinical trial in treatment-seeking alcohol-dependent individuals.

Public Health Relevance Statement:
The proposed STTR project represents a collaboration between the small business Natural Pharmacia International, Inc. and McLean Hospital to ramp up production of Alkontrol-herbal and conduct a clinical trial in treatment-seeking alcohol dependent, heavy-drinking individuals.

Project Terms:
Accidents; Acute; Adverse effects; Alcohol abuse; alcohol abuse therapy; Alcohol consumption; Alcohol dependence; alcohol seeking behavior; alcohol use disorder; Alcoholic beverage heavy drinker; Alcoholism; Alcohols; analytical method; assault; Attention; Award; Back; binge drinker; binge drinking; Biological Assay; Biological Availability; Biological Markers; Biotechnology; Botanicals; Businesses; Cessation of life; China; Clinical Research; Clinical Trials; Collaborations; college; commercialization; daidzin; Development; Dose; drinking; Drug Kinetics; efficacy study; FDA approved; Fetal Alcohol Syndrome; Heavy Drinking; High Pressure Liquid Chromatography; Homicide; Hospitals; human subject; Human Volunteers; Individual; Injury; Institutional Review Boards; International; Isoflavones; Kudzu; Label; Laboratories; Laboratory Study; Legal patent; Measures; medical schools; medication compliance; Methods; Modeling; Monitor; Morbidity - disease rate; Motor; Names; National Institute on Alcohol Abuse and Alcoholism; Outpatients; Pattern; Performance; Persons; Pharmaceutical Preparations; Phase; Plants; Plasma; Population; Positioning Attribute; Precipitation; Preparation; Primary Health Care; Procedures; Process; product development; Production; Property; Protocols documentation; Public Health; Publishing; Pueraria lobata; puerarin; Quality Control; Ramp; Reporting; Research Infrastructure; Safety; safety study; scale up; sexual assault; Sleep Wake Cycle; Small Business Technology Transfer Research; Source; Standardization; Testing; Time; treatment duration; urinary; Vertebral column; Work